Known targets — ChEMBL curated mechanism
ACVR1ADORA1ADORA2AADORA2BADORA3ESR1ESR2FLT3GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSC1HRH1HTR7IDH1IDH2IRAK1JAK1JAK2JAK3MEN1OPRM1P2RX3PDE5ASCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASIGMAR1SLC6A2SYKTACR1TOP2ATYK2
The experimentally established mechanism targets of Ethoheptazine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 known ✓ | P35372 | 10/20 | 0.71 |
| ▸ | OPRD1 | P41143 | 4/20 | 0.71 |
| ▸ | OPRK1 | P41145 | 4/20 | 0.71 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.71 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.71 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.71 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.71 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.57 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.57 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.57 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ethoheptazine SCHEMBL24581 | 0.89 | OPRM1 (0.90) | OPRM1OPRD1OPRK1SLC22A1SLC6A4 | |
| Meperidine SCHEMBL25431 | 0.84 | OPRM1 (1.00) | OPRM1OPRD1OPRK1SLC22A1SLC6A4 | |
| Meperidine SCHEMBL1083668 | 0.83 | OPRM1 (1.00) | OPRM1OPRD1OPRK1SLC22A1SLC6A4 | |
| Meperidine SCHEMBL41046 | 0.83 | OPRM1 (1.00) | OPRM1OPRD1OPRK1SLC22A1SLC6A4 | |
| Meperidine SCHEMBL2860723 | 0.83 | OPRM1 (1.00) | OPRM1OPRD1OPRK1SLC22A1SLC6A4 | |
| Meperidine SCHEMBL194412 | 0.83 | OPRM1 (1.00) | OPRM1OPRD1OPRK1SLC22A1SLC6A4 | |
| Meperidine SCHEMBL28905219 | 0.83 | OPRM1 (0.97) | OPRM1OPRD1OPRK1SLC22A1SLC6A4 | |
| Meperidine SCHEMBL3054250 | 0.82 | OPRM1 (0.94) | OPRM1OPRD1OPRK1SLC22A1SLC6A4 | |
| Meperidine SCHEMBL28695347 | 0.82 | OPRM1 (0.94) | OPRM1OPRD1OPRK1SLC22A1SLC6A4 | |
| SCHEMBL12369091 | 0.79 | OPRM1 (0.72) | OPRM1OPRD1OPRK1SLC22A1SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230001128-A1 | AEROSOLIZATION SYSTEMS, METHODS, AND APPARATUSES | SHUSTER GARY STEPHEN (CA) | 2023-01-05 | — | — | US | disclosed |
| EP-2272508-B1 | Pharmaceutical formulations for dry powder inhalers | VECTURA LTD (GB) | 2020-03-25 | — | — | EP | disclosed |
| US-10561613-B2 | Method of making particles for use in a pharmaceutical composition | VECTURA LIMITED (GB) | 2020-02-18 | — | — | US | disclosed |
| EP-2266549-B1 | METHOD OF MAKING PARTICLES FOR USE IN A PHARMACEUTICAL COMPOSITION | VECTURA LTD (GB) | 2019-08-07 | — | — | EP | disclosed |
| EP-1296651-B2 | METHOD OF MAKING PARTICLES FOR USE IN A PHARMACEUTICAL COMPOSITION | VECTURA LTD (GB) | 2019-07-17 | — | — | EP | disclosed |
| US-20180055772-A1 | Method Of Making Particles For Use In A Pharmaceutical Composition | VECTURA LTD (GB) | 2018-03-01 | — | — | US | disclosed |
| EP-1913939-B1 | Formulations for use in inhaler devices | VECTURA LTD (GB) | 2017-05-31 | — | — | EP | disclosed |
| US-9566239-B2 | Pharmaceutical formulations for dry powder inhalers | VECTURA LIMITED (GB) | 2017-02-14 | — | — | US | disclosed |
| US-20160243039-A1 | Method Of Making Particles For Use In A Pharmaceutical Composition | VECTURA LTD (GB) | 2016-08-25 | — | — | US | disclosed |
| US-9351928-B2 | Method of making particles for use in a pharmaceutical composition | VECTURA LIMITED (GB) | 2016-05-31 | — | — | US | disclosed |
| EP-1276472-A2 | FORMULATIONS FOR USE IN INHALER DEVICES | Vectura Limited (GB) | 2003-01-22 | — | — | EP | disclosed |
| WO-2002000197-A1 | METHOD OF MAKING PARTICLES FOR USE IN A PHARMACEUTICAL COMPOSITION | VECTURA LIMITED (GB) | 2002-01-03 | — | — | WO | disclosed |
| WO-2001082906-A1 | POWDERS FOR USE IN A DRY POWDER INHALER | VECTURA LIMITED (GB) | 2001-11-08 | — | — | WO | disclosed |
| WO-2001078695-A2 | PHARMACEUTICAL FORMULATIONS FOR DRY POWDER INHALERS | VECTURA LIMITED (GB) | 2001-10-25 | — | — | WO | disclosed |
| WO-2001078696-A2 | FORMULATIONS FOR USE IN INHALER DEVICES | VECTURA LIMITED (GB) | 2001-10-25 | — | — | WO | disclosed |
| WO-2001078694-A2 | FORMULATIONS FOR USE IN INHALER DEVICES | VECTURA LIMITED (GB) | 2001-10-25 | — | — | WO | disclosed |
| EP-0805680-A2 | COMBINATIONAL DRUGS FOR TREATING MIGRAINE AND OTHER ILLNESSES, COMPRISING SESQUITERPENE LACTONES AND B-COMPLEX VITAMINS | Ashbury Research Corporation (CA) | 1997-11-12 | — | — | EP | disclosed |
| WO-1996022774-A2 | COMBINATIONAL DRUGS FOR TREATING MIGRAINE AND OTHER ILLNESSES, COMPRISING SESQUITERPENE LACTONES AND B-COMPLEX VITAMINS | ASHBURY RESEARCH CORPORATION (CA) | 1996-08-01 | — | — | WO | disclosed |
| EP-0098041-B1 | SESQUITERPENE LACTONES, EXTRACTS CONTAINING THEM, THEIR PREPARATION AND PHARMACEUTICAL USE | R.P. SCHERER CORPORATION (US) | 1989-08-02 | — | — | EP | disclosed |
| US-4758433-A | Oil extract of Tanacetum parthenium for treating migraine | R. P. SCHERER CORP. (US) | 1988-07-19 | — | — | US | disclosed |